Guideline Central Blog

• Lumryz (Avadel)
  • Indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

• Arexvy(GlaxoSmithKline)
  • Prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

• Mydcombi (Eyenovia) 
  • For inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired.

• Farxiga (AstraZeneca)Expanded Indication
  • To include treatment of heart failure (HF) across the full spectrum of left-ventricular ejection fraction (LVEF) ― including HF with mildly reduced ejection fraction (HFmrEF) and with preserved ejection fraction (HFpEF).

• Elfabrio (Chiesi / Protalix)
  • To treat adults with confirmed Fabry disease.

• Rexulti (Otsuka / Lundbeck)New Indication
  • Agitation associated with Alzheimer’s disease (AD).

• Veozah (Astellas)
  • Treatment of moderate to severe hot flashes in menopausal women.

• Skinvive by Juvéderm (Allergan)
  • To improve skin smoothness of the cheeks in adults over the age of 21.

• Rinvoq (AbbVie) New Indication
  • For adults with moderately to severely active Crohn’s disease whose condition failed to respond adequately or who can’t tolerate one or more tumor necrosis factor (TNF) inhibitors.

• Vyjuvek (Krystal Biotech)
  • Treatment of patients six months of age or older with dystrophic epidermolysis bullosa (DEB).

• Ayvakit (Blueprint Medicines Corporation)New Indication 
  • Treatment of adults with indolent systemic mastocytosis (ISM).

• Cyltezo Pen (Boehringer Ingelheim)New delivery mechanism as biosimilar to Humira 
  • Multiple as biosimilar to Humira.

• CMeibo (Bausch + Lomb)
  • To treat the signs and symptoms of dry eye disease (DED).

• Opvee (Indivior)  
  • For the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression.

• Brixadi (Braeburn)
  • Extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with a transmucosal buprenorphine-containing product.

• Xacduro (Innoviva)  
  • For intravenous use in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

• Yuflyma (Celltrion USA)Biosimilar to Humira 
  • Multiple as biosimilar to Humira.

• Paxlovid (Pfizer)  
  • Treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

• Inpefa (Lexicon Pharmaceuticals)
  • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

• Abrysvo (Pfizer)  
  • For the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

---

Copyright © 2023 Guideline Central, All rights reserved.